Hasil Pencarian  ::  Simpan CSV :: Kembali

"Pendahuluan : Kemoradiasi pada kanker rektum menghasilkan radical oxygen species (ROS) yang dapat memicu kematian sel. ALDH1A1 merupakan antioksidan yang mampu mengurangi ROS dan merupakan marker sel punca kanker. Penelitian ini bertujuan untuk mengetahui hubungan kadar ALDH1A1 dengan respon kemoradiasi berdasarkan metode RECIST 1.1 pada pasien kanker rektum stadium lanjut lokal. Metode : Penelitian ini merupakan studi retrospektif terhadap 14 pasien kanker rektum stadium lanjut lokal yang memenuhi kriteria inklusi dari januari 2012 sampai januari 2015. ALDH1A1 diperiksa menggunakan metode ELISA dari sampel blok parafin kanker rektum. Respon pengecilan tumor dari CT scan dan MRI dihitung berdasarkan metode RECIST 1.1. Hasil : Didapatkan rerata kadar ALDH1A1 sebesar 9,014 ± 3,3 pg/mL, rerata persentase respon radiasi 7,89 ± 35,7 % dan diklasifikasikan berdasarkan RECIST didapatkan proporsi respon parsial sebesar 28,6 % , respon stabil sebesar 50% dan respon progresif sebesar 21,4%. Terdapat korelasi negatif kuat yang bermakna (r = - 0,890 dan p < 0,001) antara kadar ALDH1A1 dengan respon kemoradiasi berdasarkan RECIST. Kesimpulan : pada penderita kanker rektum stadium lanjut lokal respon kemoradiasi dipengaruhi oleh kadar ALDH1A1 dalam jaringan tumor. Semakin tinggi kadar ALDH1A1 semakin buruk respon kemoradiasi.

---

Introduction : Chemoradiation in rectal cancer produce radical oxygen species (ROS) wich can cause cell death. ALDH1A1 is an antioxidant that can reduce ROS and known as cancer stem cell marker. The purpose of this study is to determine the correlation between ALDH1A1 level with tumor shrinkage using RECIST methode in locally advance rectal cancer.

Methode : This is a retrospective study to 14 locally advance rectal cancer patients who meet the inclusion criteria from january 2012 to january 2015. ALDH1A1 level was measured by ELISA from paraffin embeded tissue. Tumor shrinkage was measured from CTscan or MRI using RECIST 1.1 methode.

Result : The mean ALDH1A1 level is 9,014 ± 3,3 pg/mL, the mean of tumor shrinkage is 7,89 ± 35,7 %, Partial respond proportion is 28,6 % , Stable dissease proportion is 50% and progressive dissease proportion is 21,4%. There was a significant strong negative correlation (r = -0,890, p < 0,001) between ALDH1A1 with tumor shrinkage.

Conclusion : This study showed that tumor shrinkage in locally advanced rectal cancer after chemoradiation is influenced by ALDH1A1 level. The increase od ALDH1A1 level will decrease tumor shrinkage after chemoradiation."

"Tujuan: Penelitian ini bertujuan untuk mengetahui distribusi dan karakteristik kejadian COVID-19 pada pasien dan tenaga kesehatan/pekerja di IPTOR RSUPN dr. Cipto Mangunkusumo dan juga dampak COVID-19 terhadap luaran terapi berdasarkan kriteria RECIST dan toksisitas radiasi berdasarkan kriteria RTOG pada pasien kanker serviks yang menjalani radioterapi di IPTOR RSUPN dr. Cipto Mangunkusumo.Metode: Studi eksploratif retrospektif dari 835 pasien kanker serviks yang terdaftar di IPTOR RSUPN dr. Cipto Mangunkusumo, dari Juli 2020 hingga Maret 2022. Melalui analisis kriteria inklusi dan eksklusi, didapatkan sampel 506 pasien yang terdiri dari 77 pasien terkonfirmasi COVID-19 dan 429 pasien yang tidak terpapar COVID-19, serta data insidensi terkonfirmasi COVID-19 dari seluruh pasien kanker, insiden COVID-19 di poliklinik serta insiden terkonfirmasi COVID-19 tenaga kesehatan dan pekerja di IPTOR RSUPN dr. Cipto Mangunkusumo.Hasil: Diketahuinya gambaran infeksi COVID-19 pada pasien dan tenaga kesehatan serta pekerja di RSUPN dr. Cipto Mangunkusumo. Juga, telah dilakukan penilaian luaran terapi berdasakran kriteria RECIST terhadap pasien kanker serviks terkonfirmasi COVID-19 maupun yang tidak terkonfirmasi COVID-19 pada 2 minggu serta ≥ 3 bulan pasca radiasi. Ditemukan bahwa status COVID-19 pada pasien kanker serviks tidak berpengaruh signifikan (p>0,05) terhadap luaran terapi 2 minggu setelah radiasi, namun meningkatkan peluang CR sebesar 1,120 OR (95% CI: 0,645-1,943). Lebih lanjut, pada luaran ≥ 3 bulan pasca radiasi, status COVID-19 berpengaruh signifikan (p<0,05) dan meningkatkan peluang CR sebesar 1,157 OR (95% CI: 1,09-1,223) Sementara itu, juga telah dilakukan penilaian antara toksisitas radiasi terhadap pasien kanker serviks terkonfirmasi COVID-19 maupun yang tidak COVID-19, di mana ditemukan bahwa status COVID-19 tidak berpengatuh signifikan (p>0,05) terhadap toksisitas radiasi, namun status COVID-19 positif ditemukan dapat meningkatkan peluang terjadinya toksisitas radiasi sebesar 1,348 (0,78-2,30) OR (95% CI).Kesimpulan: Berdasarkan pengumpulan dan analisis data dari penelitian ini, ditemukan bahwa infeksi COVID-19 memiliki pengaruh untuk tercapainya luaran terapi yang lebih baik pada pasien kanker serviks yang mendapatkan radioterapi.

---

Objective: This study aims to determine the distribution and characteristics of COVID-19 incident in patients and clinicians/workers at IPTOR RSUPN dr. Cipto Mangunkusumo. Also, this study aims to investigate the impact of COVID-19 on radiotherapy outcome based on RECIST criteria and radiation toxicity based on RTOG criteria in cervical cancer patients undergoing radiotherapy at IPTOR RSUPN dr. Cipto Mangunkusumo.

Method: An exploratory retrospective study of 835 cervical cancer patients registered at IPTOR RSCM, from July 2020 to March 2022. Through analysis of inclusion and exclusion criteria, a sample of 506 patients was obtained, consisting of 77 COVID-19 confirmed patients and 429 non-exposed COVID-19 patients, as well as data on the incidence of COVID-19 confirmed cases among cervical cancer patients, outpatients, and healthcare workers and staff at IPTOR RSCM.

Results: This study showed an overview of COVID-19 infections in all patients and hospital staffs from Departement of Radiation Oncology Cipto Mangunkusumo Hospital. Also, in this study we assess the radiotherapy outcome according to RECIST criteria for cervical cancer patients with COVID-19 and those who were not confirmed with COVID-19 at 2 weeks and ≥ 3 months after radiation. We found that COVID-19 in patients with cervical cancer had no significant impact (p>0.05) on therapy outcomes 2 weeks after radiation, but it increased the chance of CR by 1.120 OR (95% CI: 0.645-1.943). For RECIST ≥ 3 months post-radiation, COVID-19 status had a significant impact (p<0.05) and increased the chance of CR by 1.157 OR (95% CI: 1.09-1.223). Meanwhile, an assessment was also carried regarding radiation toxicity in cervical cancer patients confirmed with COVID-19 and those without COVID-19, and it was found that COVID-19 status did not have a statistically significant impact (p>0.05) on RTOG toxicity but positive COVID-19 status increased the chance of radiation-related toxicity by 1.348 (0.78-2.30) OR (95% CI).

Conclusion: Based on the data from this study, COVID-19 infection has an impact on the outcomes of cervical cancer patients who receive radiation therapy."

"Latar Belakang: Kanker serviks merupakan keganasan yang sering ditemukan diberbagai negara pada wanita setelah kanker payudara. Kanker serviks berhubungan dengan angka kematian yang tinggi. FIGO merekomendasikan penggunaan MRI sebagai alat diagnosis dan prognosis. Tingkat proliferasi tumor berhubungan dengan respon terapi yang dapat diketahui dengan nilai signal intensitas sekuens T2WI. Saat ini belum ada penelitian yang menilai perbedaan nilai SI sekuens T2WI dengan respon terapi radiasi pada kanker serviks tipe karsinoma sel skuamosa. Tujuan: Memperoleh perbedaan nilai rasio sekuens T2WI pada pasien kanker serviks karsinoma sel skuamosa yang mengalami respon dan tidak respon terapi. Metode: Sebanyak 39 subjek penelitian dilakukan pemeriksaan MRI pelvis sebelum dan setelah terapi radiasi. Data penelitian diambil menggunakan sekuens T2WI dan data histologi berasal dari EHR RSUPN Dr. Cipto Mangunkusumo. Dilakukan analisis data menggunakan uji normalitas Saphiro-Wilk dan uji T berpasangan. Hasil: Pada kelompok umur, status pernikahan, status obstetri dan klasifikasi FIGO, didapatkan hasil tidak signifikan (p = 0,19, p = 0,348, p = 0,153, dan p = 0,995; p > 0,05). Begitupun pada kelompok respon dan tidak respon dengan RECIST 1.1, didapat hasil signifkan dengan p = 0,000; p < 0,05) sedangkan pada kelompok perbedaan nilai rasio sekuens T2WI, didapatkan hasil yang tidak signifikan (p = 0,436, p > 0,05). Kesimpulan: Tidak terdapat perbedaan nilai rasio sekuens T2WI pada kelompok respon dan tidak respon terapi berdasarkan kriteria RECIST 1.1 pada kanker serviks tipe karsinoma sel skuamosa.

---

Background: Cervical cancer is a malignancy that is often found in various countries in women after breast cancer. Cervical cancer is associated with a high mortality rate. FIGO recommends the use of MRI as a diagnostic and prognostic tool. The rate of tumor proliferation is related to the therapeutic response which can be determined by the value of the T2WI sequence intensity signal. Currently, there are no studies that assess the differences in SI values of T2WI sequences and the response to radiation therapy in squamous cell carcinoma type cervical cancer.

Objective: Obtain differences in the value of the T2WI sequence ratio in patients with cervical cancer squamous cell carcinoma who experienced and did not respond to therapy.

Methods: A total of 39 study subjects were subjected to pelvic MRI examinations before and after radiation therapy. The research data were taken using T2WI sequences and histological data came from EHR RSUPN Dr. Cipto Mangunkusumo. Data were analyzed using the Saphiro-Wilk normality test and paired T test.

Results: In the age group, marital status, obstetric status and FIGO classification, the results were not significant (p = 0.19, p = 0.348, p = 0.153, and p = 0.995; p> 0.05). Likewise in the response dan unresponse group with RECIST 1.1, the results were significant with p = 0.000; p <0.05), while the difference in the value of the T2WI sequence ratio, the results were not significant (p = 0.436, p> 0.05).

Conclusion: There is no difference in the value of the T2WI sequence ratio in the response group and no response to therapy based on RECIST 1.1 criteria in squamous cell carcinoma type cervical cancer."